Panax Notoginseng, also known as Sanqi or Tianqi, has been traditionally used in Chinese medicine for its cardiovascular benefits, but in recent years, there is emerging scientific evidence supporting its potential role in the management of arteriosclerosis. Several preclinical studies have investigated the effects of Panax Notoginseng saponins (PNS), the main active constituents, on atherosclerosis models. These studies suggest that PNS can inhibit the progression of arterial plaque, reduce vascular inflammation, protect endothelial function, and modulate lipid metabolism. Mechanistically, PNS appear to downregulate inflammatory cytokines, decrease oxidative stress, and improve lipid profiles in animal models.

Some small-scale clinical studies in humans have explored the effects of Panax Notoginseng on blood lipid profiles and vascular health, with modest but positive findings. However, the majority of evidence is derived from laboratory and animal research rather than large, robust human trials. Systematic reviews and meta-analyses note that while the preliminary data are encouraging, more high-quality clinical trials are needed to establish efficacy and safety for arteriosclerosis in humans. Thus, the use of Panax Notoginseng for arteriosclerosis is supported by early-stage scientific evidence, but it is not yet confirmed by strong clinical data.